• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

    117.61 -2.78 (-2.31%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Palvella Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal ↗
    This clinical-stage biotech advancing therapies for rare skin diseases reported a notable insider sale amid a year of sharp stock gains. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win ↗
    Focused on therapies for rare skin diseases, this clinical-stage biotech saw a notable director purchase coincide with a decisive Phase 3 trial announcement and the closing of a $230 million equity... 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Pricing of Upsized Public Offering
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Proposed Public Offering
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill
    Tuesday's session: top gainers and losers ↗
    Via Chartmill
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    Which stocks are moving before the opening bell on Tuesday? ↗
    Via Chartmill
    News headline image
    Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗
    The biotech company reported statistically significant Phase 3 data for QTORIN gel. 
    Via Stocktwits
    News headline image
    Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
    Webcast conference call to take place tomorrow, Tuesday, February 24, 2026, at 8:00am ET 
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Inc (NASDAQ:PVLA) Reports Q3 2025 Earnings Miss, Highlights Key Clinical Milestones ↗
    Palvella Therapeutics reported a wider Q3 2025 loss, missing EPS estimates. Investors focus on its strong cash position and upcoming clinical trial data for its rare disease pipeline. 
    Via Chartmill
    Topics Earnings
    News headline image
    Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 11, 2025 ↗
     
    Via Benzinga
    News headline image
    Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.